Monte Rosa activates Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in metastatic prostate cancer - MRUS News | RalliesMonte Rosa activates Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in metastatic prostate cancer
M
MRUS• Monte Rosa updates on multiple clinical programs
- Monte Rosa Therapeutics completed enrollment and dosing in its GFORCE-1 Phase 1 study of MRT-8102 in people with elevated cardiovascular risk.
- Results were previously presented in part, with additional findings scheduled for release in H2 2026.
- Early readouts showed MRT-8102 reduced systemic inflammation, supporting broader development across sterile inflammation-driven diseases.
- Multiple Phase 2 studies are slated to start from H2 2026, including a mid-stage trial in cardiometabolic and atherosclerotic risk.
- Separately, a Phase 2a/b trial of VAV1-targeting MRT-6160 in Sjögren’s disease has been activated under Novartis.
MBX
•
